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ABSTRACT
Aim: Aim of this research was to develop and validate a simple, efficient and reproducible highperformance liquid chromatography method to measure phenytoin concentrations in human plasma
Study Design: Linearity, selectivity, sensitivity, accuracy and precision of the analytical methods
were validated according to ICH guidelines.
Methodology: The method employed a Phenomenex C18 column kept at 25ºC. The mobile phase
consisted of a 0.05 M potassium dihydrogen phosphate buffer solution (pH 2.8) and methanol in a
ratio of 60:40, respectively. The flow rate of the mobile phase was 0.7 mL/min. Phenytoin was
detected at a wavelength of 250 nm.
Results: Phenytoin was eluted at 7.4 minutes with no interference with the other components of the
human plasma. The method was linear in the range of 1-25 μg/mL (R2 = 0.9998). The LOD and
LOQ were calculated as 0.07 μg/mL and 0.20μg/mL, respectively. Recovery, tested in the range of
5-20 μg/mL, was found to be 99.21 - 102.09%. Intraday and interday precision RSDs were 0.65 and
_____________________________________________________________________________________________________
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0.29%, respectively.
Conclusion: The proposed method is fast, reliable and reproducible, and can be recommended to
measure free phenytoin levels in the blood.

Keywords: Phenytoin; HPLC; validation; human plasma.

1. INTRODUCTION

2. MATERIALS AND METHODS

Phenytoin (PHT) is an anticonvulsant medication
marketed in the U.S. as Dilantin™. This drug has
been indicated for the management of
generalized tonic-clonic seizures, complex partial
seizures, and for the prevention of seizures after
head trauma and neurosurgery [1,2]. There is
interest in examining the activity of the drug due
to its narrow therapeutic index, nonlinear
pharmacokinetics and the ability of various
compounds to modify the concentrations of
phenytoin in the blood [2-5]. Drugs in the body
exist in two forms bound and unbound. Only
unbound (free) drug reaches the active site,
interacts with receptors and produces a
therapeutic effect. Free drug is a predictor of
clinical efficacy or toxicity [6-8]. PHT is
approximately 90% bound to plasma proteins [911]. Changes in unbound concentrations of PHT
can lead to exaggerated pharmacologic
response and toxicity. The development of side
effects also correlates better with free phenytoin
concentrations than with total concentrations [1214]. PHT, as a drug with nonlinear
pharmacokinetics and narrow therapeutic index,
may
produce
major
changes
in
the
pharmacological effect with the only small
variations in its unbound plasma concentrations.
Monitoring of free PHT plasma levels is
required to avoid unexpected alterations
in pharmacologic response, to achieve the
efficacy of phenytoin and to avoid phenytoin
intoxication.
Unbound
phenytoin
plasma
concentrations
should
be
measured
in
patients rather than calculated [15]. Our
study aimed to develop a simple, efficient
and
reproducible high-performance
liquid
chromatography (HPLC) method to assess
unbound PHT levels in human plasma.
Previous studies have measured PHT levels
using HPLC methods outside plasma [16,17],
involved
solid-phase
extraction
protocols
[18] as well as detected PHT concentrations
in biological fluids [19-25]. This novel HPLC
method was used to assess free plasma
concentrations of phenytoin in drug-drug
interaction studies [26].

2.1 Chemicals and Reagents
Phenytoin
sodium
(5,5-Diphenylhydantoin
sodium salt), dimethyl sulfoxide (DMSO), HPLCgrade methanol, HPLC-grade water and 0.22 μm
Stericup™ Sterile Vacuum Filter Units were
obtained from Fisher Scientific (New Hampshire,
USA). Potassium dihydrogen phosphate and
Centrifree®
Ultrafiltration
Devices
were
purchased from EMD Millipore (Massachusetts,
USA). Human plasma was obtained from Valley
Biomedical (Virginia, USA).

2.2 Instrument
Conditions

and

Chromatographic

An Agilent 1100 series HPLC system with
autosampler and UV detector was used for the
study. A Phenomenex Kinetex C18 LC column
(250 x 4.6 mm) was operated at 25ºC. An
isocratic method was utilized to elute the analyte
with a mobile phase flow rate of 0.7 mL/min. The
injection volume was 20 µL for all
samples.Phenytoin
was
detected
at
a
wavelength of 250 nm.

2.3 Mobile Phase Preparation
The mobile phase consisted of a 0.05 M
potassium dihydrogen phosphate (KH2PO4)
buffer solution (pH adjusted to 2.8 with
phosphoric acid) and methanol (MeOH) in a
60:40, MeOH:KH2PO4 ratio. The mobile phase
was filtered using a 0.22 μm Stericup™ Sterile
Vacuum Filter Unit and degassed by a vacuum
stirring setup.

2.4 Stock
Solution
Preparation

and

Samples

Phenytoin was dissolved in HPLC-grade DMSO
to produce a stock solution of 1 mg/mL
concentration. The master stock was diluted with
filtered human plasma to produce another stock
solution of 100 μg/mL, which was further diluted
to achieve required concentrations of phenytoin.
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Human plasma was passed through Millipore
ultracentrifugation units, which were run at
2,000X g for 20 minutes. The resulting filtrate
was collected and used as a diluent for the PHT
stock solution.

sharp peak at an elution time of 7.4 min, which
was absent on the blank chromatogram (Figure
1). Other components of filtered plasma were
detected and separated by the method, allowing
proper visualization of the PHT peak. The
experiments were performed in triplicate.

3. METHOD VALIDATION
3.2 Linearity
The analytical method was validated based on
ICH Harmonised Tripartite Guideline [27].

To
determine
linearity,
eight
phenytoin
concentrations ranging from 1 to 25 μg/mL were
prepared from the stock solution. Filtered human
plasma was used to dilute the PHT stock solution
into 1, 2, 4, 6, 8, 10, 15 and 25 μg/mL
concentrations. The samples were assessed
to HPLC. The mean area for each
concentration
was
plotted
against
the
concentration (Fig. 2).

3.1 Specificity
The specificity of the method was determined by
comparing blank (plasma without PHT)
chromatogram to the chromatogram of a sample
containing a known concentration of PHT.
Analysis of the sample containing PHT showed a

Fig. 1. Blank Chromatogram (top) and Phenytoin Chromatogram (bottom): PHT concentration
is 25 μg/mL, retention time is 7.399 minutes

Area (mAU * s)

250

y = 7.718x - 0.983
R² = 0.999

200
150
100
50
0
0

5

10

15

20

25

Concentration (μg/mL)

Fig. 2. The linearity of the HPLC method
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An excellent correlation was detected between
2
the peak areas and concentrations tested (R =
0.9998). All experiments were performed in
triplicate.

μg/mL. Triplicates were made to assess the
accuracy. The results of the study are
summarized in Table 2. The mean % recoveries
of the three concentrations were found in the
range of 99.21 - 102.09%.

3.3 Limit of Detection and Limit of
Quantitation

Table 1. LOD and LOQ of the HPLC method

The limit of detection (LOD) and limit of
quantitation (LOQ) were calculated based on ICH
guidelines [11]. The following formulas were
used:

σ
S
Limit of Detection (μg/mL)
Limit of Quantitation (μg/mL)

LOD = 3.3*σ/S
LOQ = 10*σ/S

0.16
7.71
0.07
0.20

3.5 Precision / Repeatability

Where:

Precision was determined by utilizing inter- and
intraday testing. Phenytoin concentration of 25
μg/ml was used in both studies. In the intraday
study, six injections of different samples of 25 μg/
mL concentration were evaluated. In the interday
study, an injection of six different samples of the
same concentration (25 μg/mL) was done once a
day for six consecutive days. The results of the
study are summarized in Table 3. The results
have been demonstrated low relative standard
deviations (RSD) that indicate a precise method
[28].

σ- refers to the standard deviation of the yintercept of the calibration curve
S- refers to the slope of the calibration curve.
The calculated LOD and LOQ were at 0.07
μg/mL and 0.20 μg/mL, respectively (Table 1).

3.4 Accuracy
Accuracy study was performed with PHT
concentrations of 5 μg/mL, 10 μg/mL and 20

Table 2. Accuracy of the HPLC Method
Sample
1

2

3

PHT concentration
(μg/mL)
5

10

20

Measured PHT
Concentration(μg/mL)
5.01
5.03
5.03
9.93
9.91
9.92
20.26
20.63
20.36

% Recovery
100.28
100.67
100.68
99.27
99.15
99.22
101.28
103.17
101.81

Mean %
Recovery
100.55

99.21

102.09

Table 3. Precision of the HPLC method
Sample
1
2
3
4
5
6
Mean
SD*
%RSD**

Intraday Concentration(μg/mL)
25.15
24.90
24.80
24.85
25.25
25.03
24.99
0.16
0.65

Interday Concentration(μg/mL)
25.13
25.14
25.03
25.16
25.01
24.97
25.07
0.07
0.29

*SD is Standard Deviation
**RSD is Relative Standard Deviation

4
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Table 4. Stability of phenytoin
Initial
PHT concentration (μg/mL)
RT, 4h
5
25

5.06
25.17

Stability conditions
Human plasma
4℃, 24 h -30℃, 7days Freeze-Thaw
PHT concentrations (μg/mL)
5.01
5.41
5.01
25.19
25.13
25.33

3.6 Stability

COMPETING INTERESTS

The stability of phenytoin in human plasma
was evaluated and the results are reported in
Table 4.

Authors have
interests exist.

declared

that

Mobile phase
4ºC 24 h
4.99
25.34

no

competing
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